<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945436</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00105125</org_study_id>
    <secondary_id>R01DA041032-02</secondary_id>
    <nct_id>NCT02945436</nct_id>
  </id_info>
  <brief_title>Optimizing HIV Counseling and Testing and Referral Through an Adaptive Drug Use Intervention</brief_title>
  <acronym>Swerve</acronym>
  <official_title>Optimizing HIV Counseling and Testing and Referral Through an Adaptive Drug Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A sample of 600 young (15-29) men who have sex with men (MSM) and transgender persons living
      in South-East Michigan's Detroit Metro Area (DMA) will be recruited through venue-based
      sampling and online ads to examine the efficacy of adding a substance use brief intervention
      (SUBI) to standard HIV prevention and care (SOC) for achieving gains in successful engagement
      in HIV care. The investigators will partner with Detroit-area AIDS Service Organizations
      (ASOs) to deliver the intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research activities involve a prospective 4-arm factorial RCT (SOC-only, SOC+SUBI,
      SUBI+SOC, SUBI+SUBI) of approximately 600 ATOD-using high-risk YMSM aged 15-29 in the DMA.
      The intervention comprises of two intervention visits, at which time participants may get
      either standard of care only (SOC-only) or standard of care plus SUBI. All participants will
      receive standard of care (SOC; i.e., Comprehensive HIV Testing and Counseling) at each visit.
      The substance use brief intervention (SUBI) will be added to SOC within the experimental
      arms. At intervention visit one, standard of care is the same for all participants: standard
      of care is Counseling Testing and Referral (CTR).CTR is a standardized service in which
      counselors provide HIV testing, risk-related counseling and appropriate referrals (medical,
      social, prevention, and partner services) to clients. Hence at visit one, 300 YMSM will
      receive CTR and 300 YMSM will receive CTR+SUBI. The investigators expect approximately 10-15%
      of participants to test HIV positive at intervention visit one. For intervention visit two,
      standard of care is sero-status specific. For HIV-negatives standard of care remains CTR. For
      HIV-positives standard of care is case management, as offered routinely by each ASO, which
      involves counseling on linkage to care and the importance of care retention. To examine how
      the sequencing and dosing of interventions impacts efficacy, the investigators propose to
      randomize at baseline into a factorial randomized controlled trial. The control arm will
      receive SOC-only at both intervention visit one and two (SOC-only). Experimental arm one
      (SOC+SUBI) will receive SOC at visit one and SUBI at visit two. Experimental arm two
      (SUBI+SOC) will receive SUBI at visit one and SOC at visit two. Experimental arm three
      (SUBI+SUBI) will receive the intervention condition at visits one and two.

      The RCT thus answers two important questions: 1) What is the impact of the addition of SUBI
      to SOC on HIV engagement in care and sexual and substance-related risk-taking behaviors among
      high-risk YMSM? and 2) What combination of services (SOC-only, SOC+SUBI, SUBI+SOC, SUBI+SUBI)
      has the greatest impact on engagement in HIV prevention? (where engagement in care is defined
      as routine HIV testing for sero-negative YMSM and linkage/retention in care for sero-positive
      MSM).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increases in repeat HIV testing</measure>
    <time_frame>18 months</time_frame>
    <description>Increases in repeat HIV testing as measured by the &quot;HIV Testing Questions&quot; section of the questionnaires</description>
  </primary_outcome>
  <other_outcome>
    <measure>Decreases in sexual risk behavior</measure>
    <time_frame>18 months</time_frame>
    <description>Decreases in sexual risk behavior as measured by the &quot;Sexual History&quot; section of the questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in substance use and abuse as measured by the &quot;Assist&quot;, &quot;Audit&quot;, &quot;Medical Marijuana&quot;, Synthetic Cannabis&quot;, &quot;Energy Drinks&quot;, and &quot;Substance Use (past 30 days)&quot; sections of the questionnaires</measure>
    <time_frame>18 months</time_frame>
    <description>Investigators will verify self-reported substance use by collecting and testing biological samples. Investigators will measure alcohol use with an Ethyl Glucuronide (ETG) urine test. Investigators will measure the use of other substances with an EZ Split Key Cup urine test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in consequences of substance use as measured by the &quot;Assist&quot;, &quot;Audit&quot; and &quot;Overdose&quot; sections of the questionnaires</measure>
    <time_frame>18 months</time_frame>
    <description>Reduction in the number of participants who experience negative consequences of substance use as measured by the &quot;Assist&quot;, &quot;Audit&quot; and &quot;Overdose&quot; sections of the questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>Decreased STI incidence</measure>
    <time_frame>18 months</time_frame>
    <description>Decreases in STI incidence as measured by the &quot;STI History&quot; section of the questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>Increase in the number of participants who have been successfully engaged in care</measure>
    <time_frame>18 months</time_frame>
    <description>The investigators define engagement in HIV care as linkage and retention in HIV care (per the Institute of Medicine guidelines of linkage, or first HIV-care related visit, within 90 days of diagnosis and at least two physician visits with a CD4 and viral load test in 12 months) and achievement of viral suppression.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HIV</condition>
  <condition>Substance Use</condition>
  <arm_group>
    <arm_group_label>SOC + SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive current standard of care (SOC) for HIV counseling, testing, and referral at both visit 1 and visit 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC + SUBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SOC at visit 1 and the experimental substance use brief intervention (SUBI) at visit 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUBI + SUBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the SUBI at both visit 1 and visit 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUBI + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the SUBI at visit 1 and SOC at visit 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Substance Use Brief Intervention</intervention_name>
    <description>SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.</description>
    <arm_group_label>SOC + SUBI</arm_group_label>
    <arm_group_label>SUBI + SUBI</arm_group_label>
    <arm_group_label>SUBI + SOC</arm_group_label>
    <other_name>SUBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of Care (SOC)</intervention_name>
    <description>Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.</description>
    <arm_group_label>SOC + SOC</arm_group_label>
    <arm_group_label>SOC + SUBI</arm_group_label>
    <arm_group_label>SUBI + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants must be ages 15-29

          -  All participants must currently reside in the DMA (verified by zip code)

          -  All participants must self-report as HIV sero-negative

          -  All participants must report at least one sexual experience with a man in the previous
             6 months

          -  All participants must report either at least one binge-drinking episode and/or use of
             illicit substances in the previous 3 months

          -  All participants must identify as either a man who has sex with men (MSM) or as
             transgender

          -  All participants must speak English

        Exclusion Criteria:

        Â°Anyone not meeting all 6 inclusion criteria will be excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Stephenson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rob Stephenson, PhD</last_name>
    <phone>734-615-0149</phone>
    <email>rbsteph@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexis Hunter, MA</last_name>
    <phone>734-764-4646</phone>
    <email>ahun@umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Sexuality and Health Disparities</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Stephenson, phD</last_name>
      <phone>734-615-0149</phone>
      <email>rbsteph@umich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Robert Stephenson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

